BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 4
• 7
• 8
• 9
• 10
• 11
• 14
• 15
• 16
• 17
• 18
• 20
• 21
• 22
• 23
• 24
• 25
• 28
• 29
• 30
• 31

• 

  Sofie
• 

  Deals

  Royalty Financing Serves as Lifeline for Some Biopharma Companies in Uncertain Market

  As traditional fundraising methods falter for smaller firms, the rise of royalty deals is reshaping how companies access capital, offering an alternative that bypasses equity dilution and debt.

  October 2, 2024

   · 

  5 min read

   · 

  Ben Hargreaves
• 

  Job Trends

  Improving Talent Recruitment, Retainment Key to Massachusetts Life Sciences: Report

  Designed to create hundreds of jobs and add up to $1 billion to Massachusetts’ gross domestic product by the start of 2030, MassBio’s five-year strategic plan addresses challenges including skill gaps and talent shortages.

  October 2, 2024

   · 

  4 min read

   · 

  Angela Gabriel
• 

  Podcast

  BMS’ Schizophrenia Approval, Pfizer’s Sudden Sickle Cell Withdrawal and Roche’s Pharma Day

  Bristol Myers Squibb wins approval for the first novel schizophrenia drug in decades; Pfizer pulls Oxbryta from the market; new IVF and abortion laws could derail women’s health research; Roche touts CDK inhibitor deal and obesity pipeline and BioSpace heads to Meeting on the Mesa.

  October 2, 2024

   · 

  1 min read

   · 

  Heather McKenzie
• 

  Manufacturing

  J&J to Invest $2B in North Carolina Manufacturing Facility, Create 420 Jobs

  Johnson & Johnson is making the investment to help meet its 2030 target of launching 20 new medicines and expanding filings for approximately 50 other products.

  October 2, 2024

   · 

  2 min read

   · 

  Tristan Manalac
• 

  Cell Therapy

  As 2seventy Nears Breakeven, CEO Chip Baird Explains How the Team Survived

  To say that 2seventy bio’s short two years of existence have been dramatic is an understatement. CEO Chip Baird told BioSpace transparency and a committed staff have kept the biotech going through thick and thin.

  October 2, 2024

   · 

  8 min read

   · 

  Annalee Armstrong
• 

  Legal

  Amgen Faces Class Action Lawsuit for Allegedly Hiding $10.7B Tax Bill From Investors

  Amgen’s motion for dismissal was denied after a New York judge agreed the company did not sufficiently disclose to shareholders back taxes and penalties owed to the Internal Revenue Service.

  October 2, 2024

   · 

  2 min read

   · 

  Tristan Manalac
• 

  Manufacturing

  Lilly to Invest $4.5B in New Indiana Manufacturing and R&D Center

  Eli Lilly’s investment in the LEAP Research and Innovation District in Lebanon, Indiana, has now jumped to more than $13 billion.

  October 2, 2024

   · 

  2 min read

   · 

  Tristan Manalac
• 

  Layoffs

  Bayer, J&J and Pfizer to Lay Off Nearly 500 Combined Employees

  Big Pharma companies Bayer and Johnson & Johnson are downsizing their New Jersey workforces while Pfizer cuts jobs in Ireland. Many of the layoffs are effective by the end of the year.

  October 2, 2024

   · 

  3 min read

   · 

  Angela Gabriel
• 

  Layoffs

  More Layoffs From ImmunityBio, Bringing California’s Fall Cuts to 31

  ImmunityBio will lay off 15 employees in California, mostly in El Segundo, effective Nov. 25. The company is also letting go 16 employees later this month.

  October 2, 2024

   · 

  1 min read

   · 

  Angela Gabriel